Thinking through the multimodal treatment of localized oesophageal cancer: the point of view of the surgeon
Thinking through the multimodal treatment of localized oesophageal cancer: the point of view of the surgeon
PURPOSE OF REVIEW: This review examines current developments and controversies in the multimodal management of oesophageal cancer, with an emphasis on surgical dilemmas and outcomes from the surgeon's perspective.
RECENT FINDINGS: Despite the advancement of oncological neoadjuvant treatments, there is still no consensus on what regimen is superior. The majority of patients may still fail to respond to neoadjuvant therapy and suffer potential harm without any survival advantage as a result. In patients who do not respond, adjuvant therapy is still often recommended after surgery despite any evidence for its benefit. We examine the implications of different regimens and treatment approaches for both squamous cell cancer and adenocarcinoma of the oesophagus.
SUMMARY: The efficacy of neoadjuvant treatment is highly variable and likely relates to variability of tumour biology. Ongoing work to identify responders, or optimize treatment on an individual patient, should increase the efficacy of multimodal therapy and improve patient outcomes.
353-361
Pucher, Philip H.
6b51dabb-77c2-40c6-bfa7-1daa3f82c0a6
Wijnhoven, Bas P.L.
c90de263-8360-44b6-9c96-939104e2a2cb
Underwood, Timothy J.
8e81bf60-edd2-4b0e-8324-3068c95ea1c6
Reynolds, John V.
5eb43169-6a80-4f67-957c-cd19318c49dc
Davies, Andrew R.
53be022e-a654-4384-83a5-6cb68b0c8479
1 July 2021
Pucher, Philip H.
6b51dabb-77c2-40c6-bfa7-1daa3f82c0a6
Wijnhoven, Bas P.L.
c90de263-8360-44b6-9c96-939104e2a2cb
Underwood, Timothy J.
8e81bf60-edd2-4b0e-8324-3068c95ea1c6
Reynolds, John V.
5eb43169-6a80-4f67-957c-cd19318c49dc
Davies, Andrew R.
53be022e-a654-4384-83a5-6cb68b0c8479
Pucher, Philip H., Wijnhoven, Bas P.L., Underwood, Timothy J., Reynolds, John V. and Davies, Andrew R.
(2021)
Thinking through the multimodal treatment of localized oesophageal cancer: the point of view of the surgeon.
Current opinion in oncology, 33 (4), .
(doi:10.1097/CCO.0000000000000751).
Abstract
PURPOSE OF REVIEW: This review examines current developments and controversies in the multimodal management of oesophageal cancer, with an emphasis on surgical dilemmas and outcomes from the surgeon's perspective.
RECENT FINDINGS: Despite the advancement of oncological neoadjuvant treatments, there is still no consensus on what regimen is superior. The majority of patients may still fail to respond to neoadjuvant therapy and suffer potential harm without any survival advantage as a result. In patients who do not respond, adjuvant therapy is still often recommended after surgery despite any evidence for its benefit. We examine the implications of different regimens and treatment approaches for both squamous cell cancer and adenocarcinoma of the oesophagus.
SUMMARY: The efficacy of neoadjuvant treatment is highly variable and likely relates to variability of tumour biology. Ongoing work to identify responders, or optimize treatment on an individual patient, should increase the efficacy of multimodal therapy and improve patient outcomes.
Text
Multimodal treatment for oesophageal cancer_final
- Accepted Manuscript
More information
Published date: 1 July 2021
Additional Information:
Publisher Copyright:
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
Copyright:
This record is sourced from MEDLINE/PubMed, a database of the U.S. National Library of Medicine
Identifiers
Local EPrints ID: 450476
URI: http://eprints.soton.ac.uk/id/eprint/450476
ISSN: 1040-8746
PURE UUID: 32264d73-57d4-4b5e-bf32-68a118e1406d
Catalogue record
Date deposited: 29 Jul 2021 16:31
Last modified: 17 Mar 2024 06:43
Export record
Altmetrics
Contributors
Author:
Philip H. Pucher
Author:
Bas P.L. Wijnhoven
Author:
John V. Reynolds
Author:
Andrew R. Davies
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics
